The 9L rat brain tumor model for pre-clinical investigation of radiation-chemotherapy interactions.
The rat 9L gliosarcoma brain tumor model has been used for more than thirty years to investigate a variety of potential therapeutic agents, combinations, schedules, and approaches that might be applicable to the management of high-grade malignant brain tumors in man. When tumor cells are implanted intracerebrally, a solid tumor grows until its mass results in the death of the animal, typically between 20 and 30 days postinoculation. Radiation therapy (either single or fractionated doses) is effective at prolonging survival in a dose-dependent manner. Numerous cancer chemotherapeutic agents, by a variety of doses, schedules, and routes of delivery, have demonstrated therapeutic efficacy in the 9L model. The combination of radiation and agents such as AZQ, BCNU, bleomycin, and cis-platinum has resulted in prolongation of survival that is significantly better than either agent used alone, without exceeding the tolerance of critical normal tissues. These pre-clinical data suggest that combining standard fractionated radiation therapy with appropriate concomitant cytotoxic chemotherapeutic agents might benefit patients with high-grade brain tumors.
Kimler
B F
BF
Department of Radiation Oncology, University of Kansas Medical Center, Kansas City.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D016227:Benzoquinones / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D002330:Carmustine / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D018316:Gliosarcoma / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use; D051381:Rats; D011916:Rats, Inbred F344; D013141:Spiro Compounds / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D009942:Organometallic Compounds; D013141:Spiro Compounds; D001761:Bleomycin; C026818:spirogermanium; D014750:Vincristine; D003520:Cyclophosphamide; C029108:diaziquone; D002945:Cisplatin; D002330:Carmustine